Beperminogene perplasmid

Drug Profile

Beperminogene perplasmid

Alternative Names: AMG 0001 01; AMG-0001; Collategene; Hepatocyte growth factor gene therapy - AnGes MG; HGF Plasmid

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AnGes MG
  • Developer AnGes MG; Osaka University Hospital
  • Class Antiparkinsonians; Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Peripheral arterial disorders
  • New Molecular Entity No
  • Available For Licensing Yes - Ischaemic heart disorders; Lymphoedema; Parkinson's disease

Highest Development Phases

  • Phase III Peripheral arterial disorders
  • Phase I/II Lymphoedema
  • Phase I Arteriosclerosis obliterans; Ischaemic heart disorders; Thromboangiitis obliterans
  • Preclinical Parkinson's disease

Most Recent Events

  • 23 Nov 2016 AnGes plans a long-term follow-up observational clinical trial for Peripheral arterial disorders (in patients with critical limb ischaemia) in USA (IM) (NCT02974179)
  • 27 Jul 2016 Osaka University Hospital terminates phase-I trial in Ischaemic heart disorders in Japan (IM) (UMIN000012942)
  • 20 Jun 2016 AnGes terminates phase III trial in Peripheral arterial disorders in USA, Belgium, Canada, Denmark, Finland, France, Hungary, Italy, Netherlands, Poland and Sweden due to amendment in global development strategy (9198317; NCT02144610)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top